Teva puts GSK and Amarin on notice with generic Lovaza launch

Lovaza--Courtesy of GlaxoSmithKline

Watch out, GlaxoSmithKline--and Amarin. Teva Pharmaceutical Industries ($TEVA) has launched its generic version of Glaxo's ($GSK) fish-oil pill, Lovaza, designed to lower triglyceride levels in patients with cardiovascular disease. Lovaza delivers $1.1 billion in U.S. sales for Glaxo annually, Teva says. But GSK isn't the only company likely to suffer from Teva's generic. Amarin's ($AMRN) rival product Vascepa will have to face the competition, too. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.